ARHGEF38

Across TCGA pan-cancer cohorts, ARHGEF38 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ARHGEF38’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARHGEF38 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGEF38 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where ARHGEF38 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF38 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	III,IV	+0.443	<.001	9	view →
LSCC	Male	All	−0.827	<.001	7	view →
PDAC	All	All	+0.595	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

ARHGEF38–LUAD

Open the LUAD breakdown →